Urticaria Treatment Guidelines

First-Line Treatment

Second-generation non-sedating H1 antihistamines are the first-line treatment for urticaria, with doses that can be increased up to four times the standard dose for inadequate symptom control, as recommended by the guideline society 1, 2
Patients should be offered at least two different non-sedating antihistamines as responses and tolerance vary between individuals, according to the British Journal of Dermatology 3, 1
Cetirizine has the shortest time to attain maximum concentration, which may be advantageous when rapid relief is needed, as noted by the British Journal of Dermatology 3

For urticaria unresponsive to high-dose antihistamines, omalizumab (anti-IgE monoclonal antibody) is recommended, with a standard starting dose of 300 mg every 4 weeks, as suggested by 1, 2
Allow up to 6 months for patients to respond to omalizumab before considering alternative treatments, according to 1, 2

For patients who do not respond to high-dose antihistamines and omalizumab, cyclosporine is recommended, with regular monitoring of blood pressure and renal function required due to potential side effects, as recommended by 1, 2
Cyclosporine is effective in about two-thirds of patients with severe autoimmune urticaria at 4 mg/kg daily for up to 2 months, according to 1

Lesional skin biopsy is essential to confirm small-vessel vasculitis histologically in urticarial vasculitis, as noted by the British Journal of Dermatology 3, 4
A full vasculitis screen, including serum complement assays for C3 and C4, is necessary to distinguish normocomplementemic from hypocomplementemic disease, according to the British Journal of Dermatology 3, 4
Serum C4 should be used as an initial screening test for hereditary and acquired C1 inhibitor deficiency in angioedema without wheals, as recommended by the British Journal of Dermatology 3
ACE inhibitors should be avoided in patients with angioedema without wheals, according to the British Journal of Dermatology 3, 2

Identify and minimize aggravating factors such as overheating, stress, alcohol, and certain medications (aspirin, NSAIDs, codeine), as suggested by the British Journal of Dermatology 3, 1, 2
NSAIDs should be avoided in aspirin-sensitive patients with urticaria, according to the British Journal of Dermatology 3, 2
Cooling antipruritic lotions (calamine or 1% menthol in aqueous cream) can provide symptomatic relief, as noted by the British Journal of Dermatology 3, 2

The British Journal of Dermatology recommends alternative options such as fexofenadine 180 mg, desloratadine 5 mg, or levocetirizine 5 mg for chronic urticaria treatment 5
The Journal of Allergy and Clinical Immunology suggests considering adding H2-antihistamines (such as cimetidine) in combination with H1-antihistamines, though evidence is limited 6
The British Journal of Dermatology advises against using topical crotamiton cream or capsaicin for chronic urticaria, as evidence does not support their use 5
The Journal of Allergy and Clinical Immunology recommends avoiding sedating first-generation antihistamines (diphenhydramine, hydroxyzine) as first-line therapy, as they cause significant sedation and cognitive impairment without superior efficacy 6

The British Journal of Dermatology suggests using emollients regularly for any associated dry skin 7

The American Academy of Allergy, Asthma, and Immunology recommends using prednisone cautiously in patients with diabetes, as it causes reversible abnormalities in glucose metabolism, and monitoring blood glucose closely during treatment 8
The American Academy of Allergy, Asthma, and Immunology advises monitoring blood pressure during prednisone treatment in patients with hypertension, as it causes fluid retention and can worsen blood pressure 8
The American Academy of Dermatology recommends avoiding prolonged corticosteroid use in patients with osteoporosis, as it causes bone loss, and considering calcium, vitamin D, and bisphosphonates for repeated courses or longer durations 9

The British Medical Association warns that systemic corticosteroids should never be used as maintenance therapy for chronic urticaria, and should only be used for short-term control during acute flares 10
The American Academy of Allergy, Asthma, and Immunology advises against long-term or repeated corticosteroid courses due to risks of adrenal suppression, growth interference in children, dermal thinning, hypertension, diabetes, Cushing syndrome, cataracts, muscle weakness, and impaired immune function 8

The American Academy of Allergy, Asthma, and Immunology recommends omalizumab 300 mg subcutaneously every 4 weeks as the next step for chronic urticaria unresponsive to high-dose antihistamines, allowing up to 6 months for response before considering alternatives 11
The American Academy of Allergy, Asthma, and Immunology reserves cyclosporine for patients who fail both high-dose antihistamines and omalizumab, requiring blood pressure and renal function monitoring every 6 weeks 11